secwatch.observer — SEC 8-K summary
======================================

Issuer:     ClearPoint Neuro, Inc. (CLPT)
CIK:        0001285550
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001285550-22-000076
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ClearPoint Neuro Q3 revenue $5.1M (+13% YoY); reaffirms FY2022 guidance
-----------------------------------------------------------------------

- Revenue of $5.1M, up 13% YoY; gross margin improved to 72% from 66%.
- Cash and short-term investments $40.5M at Sept 30, 2022; reaffirms FY2022 revenue $21-22M.
- Partner PTC's Upstaza gene therapy approved in EU; SmartFlow Neuro Cannula included in label.
- Added ~50 biologics/drug delivery partners; installed record 10 new systems YTD.
- FDA cleared ClearPoint Maestro Brain Model, Prism Neuro Laser Therapy, and navigation software v2.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/0001285550-22-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285550/000128555022000076/clpt-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001285550-22-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer